Collaboration Seeks to Optimise Bioproduction Cell Lines

Horizon Discovery Group plc has entered into an R&D partnership and license agreement with AmplyCell S.A, to evaluate the impact of AmplyCell’s BOOST cell line optimisation technology on Horizon’s parental GS (glutamine synthetase) null CHO K1 cell line.

Under the terms of the agreement, Horizon will make an upfront payment (figure not disclosed) to AmplyCell. Upon establishing a positive impact on the CHO cell line, AmplyCell will then be entitled to receive success-based development and commercial milestone payments and Horizon will have the non-exclusive worldwide rights to sublicense these BOOSTed CHO-K1 cell lines to third parties. AmplyCell is also eligible to receive tiered royalties based on the net sales of these sublicensed lines.

Terry Pizzie, Head of Commercial, Horizon Discovery said: “We are hopeful that a successful evaluation of AmplyCell’s BOOST technology will lead to incorporation of this methodology for all future bioprocessing cell lines released by Horizon and look forward to creating a long term relationship with AmplyCell.”

Geoffrey Holsbeek, CEO of AmplyCell S.A added: “AmplyCell is delighted to enter into this collaboration with Horizon. They have already demonstrated significant success in establishing biomanufacturing licensing deals around the globe and we are pleased to be able to support their drive to remain at the forefront of cell innovation.”